Tenaya Therapeutics Business Summary

Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on discovering and developing curative therapies for heart disease through three distinct platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. The company operates on a research-intensive business model, generating revenue primarily through strategic licensing and high-value research collaborations. As of March 5, 2026, Tenaya’s financial position is bolstered by a landmark $1.1 billion collaboration with Alnylam Pharmaceuticals to target genetic markers in cardiovascular disease, providing an immediate $10 million upfront payment and over $1.1 billion in potential milestones. Its lead clinical assets include TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic cardiomyopathy. Tenaya competes directly with Rocket Pharmaceuticals, Zura Bio, and Tectonic Therapeutic, positioning itself as a specialized leader in AAV9-based genetic medicine for inherited cardiac disorders. Tenaya was founded by a distinguished group of scientists from the Gladstone Institutes and UT Southwestern, including Dr. Deepak Srivastava, Dr. Benoit Bruneau, Dr. Bruce Conklin, and Dr. Eric Olson. The leadership team is headed by CEO Faraz Ali, who brings significant gene therapy commercialization experience from previous roles at REGENXBIO and bluebird bio. The technical and clinical operations are overseen by Chief Technology Officer Kee-Hong Kim, Ph.D., formerly of Agilis Biotherapeutics and Shire, and Chief Medical Officer Whit Tingley, M.D., Ph.D. The company is backed by a blue-chip investor base, including The Column Group—which remains a major shareholder with a 23.1% stake—as well as Fidelity Investments, Casdin Capital, and RA Capital Management. The Board of Directors is chaired by Dr. R. Sanders Williams and includes prominent industry figures such as Amy Burroughs and Karah Parschauer.